Docoh
Loading...

HZNP Horizon Therapeutics

APP
Utility
Methods for the Treatment of Thyroid Eye Disease
16 Sep 21
The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
David MADDEN, Kathleen GABRIEL, Guido MAGNI, Richard WOODWARD
Filed: 10 Dec 20
APP
Utility
Methods for the Treatment of Scleroderma and Related Conditions
19 Aug 21
Provided herein are antibodies against insulin-like growth factor 1 receptor (IGF-1R) and their use in methods of treatment of, and achievement of clinical outcomes in, scleroderma and forms thereof, including diffuse cutaneous systemic sclerosis.
Elizabeth THOMPSON, Srini RAMANATHAN
Filed: 4 Feb 21
APP
Utility
Methods for the Treatment of Thyroid Eye Disease
19 Aug 21
Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Jeffrey W. SHERMAN, Dennis A. BENNETT, Srini RAMANATHAN, Yan XIN, Elizabeth THOMPSON, Elizabeth O'NEILL
Filed: 3 Mar 21
GRANT
Utility
Delayed release cysteamine bead formulation, and methods of making and using same
17 Aug 21
An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
Kathlene Powell, Ramesh Muttavarapu, Ranjan Dohil
Filed: 12 Dec 18
APP
Utility
Use of Aerosolized Levofloxacin for Treating Cystic Fibrosis
29 Jul 21
Methods for treating cystic fibrosis.
Jeffery S. LOUTIT, Elizabeth E. MORGAN, Michael N. DUDLEY, David C. GRIFFITH, Olga LOMOVSKAYA
Filed: 28 Aug 20
GRANT
Utility
Topical use of levofloxacin for reducing lung inflammation
1 Jun 21
The present invention relates to methods and compositions for the treatment of pulmonary inflammation.
Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
Filed: 11 Oct 17
GRANT
Utility
Procedure for the preparation of 4-phenyl butyrate and uses thereof
25 May 21
Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric.
Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
Filed: 7 May 19
APP
Utility
Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics
29 Apr 21
The present invention relates to the field of antimicrobial agents.
David C. GRIFFITH, Michael N. DUDLEY, Mark W. SURBER, Keith A. BOSTIAN, Olga RODNY
Filed: 16 Jun 20
APP
Utility
Methods of Treating Excitotoxicity Disorders
22 Apr 21
The present disclosure relates in general to methods for the treatment of excitotoxicity disorders, using compositions comprising cysteamine or cystamine or salts or derivatives thereof in combination with an agent that inhibits or blocks glutamate/cystine antiporter xc−.
Todd C. Zankel, Amanda Anne Ko, Sara Louise Isbell
Filed: 25 Apr 19
APP
Utility
Fluoroquinolone Formulations for Cystic Fibrosis
22 Apr 21
The disclosure provides methods for treating cystic fibrosis with fluoroquinolone formulations.
Donald VANDERVANTER
Filed: 2 Feb 17
GRANT
Utility
Methods for storing cysteamine formulations and related methods of treatment
2 Feb 21
Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided.
Michael Desjardin, Mark Johnson
Filed: 15 Nov 19
GRANT
Utility
ADO-resistant cysteamine analogs and uses thereof
2 Feb 21
The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
Filed: 5 Jul 16
APP
Utility
Methods for Treating Urea Cycle Disorders
6 Jan 21
Provided are methods of administering glycerol phenylbutyrate to a patient in need thereof, wherein said patient is also being treated with a CYP3A4 substrate having a narrow therapeutic index, midazolam or a pharmaceutically acceptable salt thereof, or celecoxib.
Bruce SCHARSCHMIDT, Masoud MOKHTARANI
Filed: 13 Jul 20
APP
Utility
Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs
6 Jan 21
The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
Bruce SCHARSCHMIDT, Masoud MOKHTARANI
Filed: 9 Mar 20
APP
Utility
Methods of Treating Urea Cycle Disorders
30 Dec 20
The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration.
Bruce SCHARSCHMIDT, Masoud MOKHTARANI
Filed: 5 Mar 20
APP
Utility
Treatment of Urea Cycle Disorders In Neonates and Infants
16 Dec 20
Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.
Bruce SCHARSCHMIDT, Masoud MOKHTARANI
Filed: 26 Apr 20
APP
Utility
Reducing Immunogenicity to Pegloticase
11 Nov 20
The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase.
Jeffrey KENT, Brian LAMOREAUX
Filed: 28 Jul 20
GRANT
Utility
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
2 Nov 20
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided.
Theresa Rosario-Jansen, David Erick Wright
Filed: 18 Nov 18
GRANT
Utility
Use of aerosolized levofloxacin for treating cystic fibrosis
5 Oct 20
Methods for treating cystic fibrosis.
Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
Filed: 30 Jan 19
APP
Utility
Methods for Storing Cysteamine Formulations and Related Methods of Treatment
19 Aug 20
Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided.
Michael DESJARDIN, Mark JOHNSON
Filed: 14 Nov 19
Patents are sorted by USPTO publication date, most recent first